Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 20, Issue 9, Pages 1027-1034
Publisher
Springer Nature
Online
2014-09-01
DOI
10.1038/nm.3667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
- (2013) Alejandro Vazquez-Martin et al. Scientific Reports
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- (2012) A. B. Cortot et al. CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
- (2012) Y. Suehara et al. CLINICAL CANCER RESEARCH
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
- (2012) C. M. Lovly et al. Science Translational Medicine
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer
- (2011) X. Yang et al. CANCER RESEARCH
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
- (2011) Zengliu Su et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
- (2010) Z. Chen et al. CANCER RESEARCH
- Insulin Receptor Substrate Regulation of Phosphoinositide 3-Kinase
- (2010) H. E. Metz et al. CLINICAL CANCER RESEARCH
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- The Sequence Alignment/Map format and SAMtools
- (2009) H. Li et al. BIOINFORMATICS
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
- (2009) Mark J Mulvihill et al. Future Medicinal Chemistry
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantifying synergism/antagonism using nonlinear mixed-effects modeling: A simulation study
- (2007) John C. Boik et al. STATISTICS IN MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started